Physician profile
Alejandro J Ramirez
NPI 1386817682
$2,161.86
in general payments reported to CMS, 2019-2025
12 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,331 · 2020: $14.27 · 2021: $290 · 2022: $257 · 2023: $166 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $269.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,083.20 | 2019-2022 | |
| Glaukos Corporation | $348.76 | 2022-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $213.36 | 2019-2021 | |
| Optos, INC. | $124.74 | 2019 | |
| Lkc Technologies, INC. | $82.46 | 2025 | |
| Rxsight INC | $77.64 | 2021 | |
| Allergan, INC. | $72.29 | 2019 | |
| Sight Sciences, INC. | $67.26 | 2021 | |
| Ivantis, INC | $35.90 | 2021 | |
| Bausch & Lomb Americas INC. | $21.23 | 2025 | Infuse |
| Iridex Corporation | $20.75 | 2021 | |
| Abb Con-Cise Optical Group LLC | $14.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.